SEC Comment Letter 0000000000-22-013340 to InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc.
Date: Dec. 12, 2022 · CIK: 0001728328 · Accession: 0000000000-22-013340
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268700
Letter
United States securities and exchange commission logo December 12, 2022 Eric Adams President and Chief Executive Officer InMed Pharmaceuticals Inc. Suite 310 - 815 West Hastings Street Vancouver, British Columbia, Canada V6C 1B4 Re:InMed Pharmaceuticals Inc. Registration Statement on Form S-1 Filed December 7, 2022 File No. 333-268700 Dear Eric Adams: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian P. Fenske
Show Raw Text
United States securities and exchange commission logo
December 12, 2022
Eric Adams
President and Chief Executive Officer
InMed Pharmaceuticals Inc.
Suite 310 - 815 West Hastings Street
Vancouver, British Columbia, Canada
V6C 1B4
Re:InMed Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed December 7, 2022
File No. 333-268700
Dear Eric Adams:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian P. Fenske